Could Smarter Data Help More Donated Kidneys Reach Patients? Valiant AI Thinks So

From Orlando, a healthcare technology startup is taking aim at one of transplantation’s most persistent challenges: ensuring that as many donated kidneys as possible are successfully transplanted into patients who need them.

Valiant AI, based in Orlando, Florida, is developing artificial intelligence tools designed to support organ procurement organizations and transplant centers in the kidney allocation process. The company focuses on helping professionals manage large volumes of clinical, logistical, and donor-recipient data within the limited time window that often defines transplant decision-making.

For decades, the transplant community has worked to address a difficult reality. Thousands of patients remain on kidney transplant waiting lists, while some donated kidneys are not ultimately transplanted. The reasons are well known within the field and include the complexity of evaluating donor and recipient compatibility, time-sensitive logistics, geographic constraints, and rapidly changing clinical conditions.

Valiant AI is building technology intended to support this process by analyzing donor information, organ viability indicators, recipient factors, and allocation logistics in real time. The goal is not to replace clinical judgment, but to provide additional insight that may help transplant professionals make more informed and timely decisions.

The company was founded by CEO Richard Threlkeld, PhD, CTO Lirim Ashiku, PhD, and COO Whitney Threlkeld, RN, OTR/L. The leadership team brings together experience across artificial intelligence, systems engineering, and clinical healthcare practice.

Richard Threlkeld’s background spans artificial intelligence research, defense technology, and advanced engineering systems. Lirim Ashiku’s work has focused on organ allocation, machine learning applications, donor authorization, and predictive modeling in transplantation. Whitney Threlkeld contributes clinical and operational experience as a registered nurse and occupational therapist, helping ground the company’s technology in real-world healthcare workflows.

Together, the founders share a long-term vision of improving how life-saving organs are allocated and used. While that broader goal reflects challenges that extend across the entire transplant system, Valiant AI’s current focus is on building decision-support tools that can help increase efficiency and improve organ utilization within existing clinical workflows.

The company states that its technology is already being used in collaboration with transplant stakeholders to explore opportunities for improving kidney placement and identifying organs that may otherwise be difficult to allocate. Early work in this area reflects a growing interest across healthcare in applying artificial intelligence to complex, time-sensitive medical decision-making.

For transplant professionals, organ procurement organizations, and transplant centers, the question is not whether the allocation system is broken, but how it can be improved to maximize the impact of every donated organ.

Valiant AI is positioning itself within that conversation, offering tools designed to support, not replace, the expertise of clinicians working under significant time and information constraints.

The broader challenge remains unchanged, but efforts like these reflect a growing push to use technology in ways that may help more donated organs reach the patients who need them most.

As the field continues to evolve, transplant leaders and professionals interested in learning more about Valiant AI can connect with the team, follow their LinkedIn page, engage with ongoing updates, and request a demo of their platform:

Follow Valiant AI on LinkedIn: https://www.linkedin.com/company/valiantai/

Learn more about Valiant AI or request a demo: www.valiantai.co